β6-integrin serves as a novel serum tumor marker for colorectal carcinoma

Beitrag in einer Fachzeitschrift


Details zur Publikation

Autorinnen und Autoren: Bengs S, Becker E, Busenhart P, Spalinger MR, Raselli T, Kasper S, Lang S, Atrott K, Mamie C, Vavricka SR, von Boehmer L, Knuth A, Tuomisto A, Mäkinen MJ, Hruz P, Turina M, Rickenbacher A, Petrowsky H, Weber A, Frei P, Halama M, Jenkins G, Sheppard D, Croner RS, Christoph J, Britzen-Laurent N, Naschberger E, Schellerer V, Stürzl M, Fried M, Rogler G, Scharl M
Zeitschrift: International Journal of Cancer
Jahr der Veröffentlichung: 2019
Band: 145
Heftnummer: 3
Seitenbereich: 678-685
ISSN: 0020-7136


Abstract

Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide and the need for novel biomarkers and therapeutic strategies to improve diagnosis and surveillance is obvious. This study aims to identify β6-integrin (ITGB6) as a novel serum tumor marker for diagnosis, prognosis, and surveillance of CRC. ITGB6 serum levels were validated in retro- and prospective CRC patient cohorts. ITGB6 serum levels were analyzed by ELISA. Using an initial cohort of 60 CRC patients, we found that ITGB6 is present in the serum of CRC, but not in non-CRC control patients. A cut-off of ≥2 ng/mL ITGB6 reveals 100% specificity for the presence of metastatic CRC. In an enlarged study cohort of 269 CRC patients, ITGB6 predicted the onset of metastatic disease and was associated with poor prognosis. Those data were confirmed in an independent, prospective cohort consisting of 40 CRC patients. To investigate whether ITGB6 can also be used for tumor surveillance, serum ITGB6-levels were assessed in 26 CRC patients, pre- and post-surgery, as well as during follow-up visits. After complete tumor resection, ITGB6 serum levels declined completely. During follow-up, a new rise in ITGB6 serum levels indicated tumor recurrence or the onset of new metastasis as confirmed by CT scan. ITGB6 was more accurate for prognosis of advanced CRC and for tumor surveillance as the established marker carcinoembryonic antigen (CEA). Our findings identify ITGB6 as a novel serum marker for diagnosis, prognosis, and surveillance of advanced CRC. This might essentially contribute to an optimized patient care.


FAU-Autorinnen und Autoren / FAU-Herausgeberinnen und Herausgeber

Christoph, Jan
Naschberger, Elisabeth PD Dr.
Lehrstuhl für Medizinische Informatik
Medizinische Fakultät
Schellerer, Vera PD Dr.
Chirurgische Klinik
Stürzl, Michael Prof. Dr.
Professur für Molekulare und Experimentelle Chirurgie


Einrichtungen weiterer Autorinnen und Autoren

Gastroenterologie Bethanien
Hamad Medical Corporation
Klinik für Gastroenterologie und Hepatologie
Oulun Yliopisto / University of Oulo
Stanford University
Universitätsklinikum Magdeburg A.ö.R.
Universitätsspital Basel
Universitätsspital Zürich (USZ)
University of California San Francisco (UCSF)
University of Nottingham


Zitierweisen

APA:
Bengs, S., Becker, E., Busenhart, P., Spalinger, M.R., Raselli, T., Kasper, S.,... Scharl, M. (2019). β6-integrin serves as a novel serum tumor marker for colorectal carcinoma. International Journal of Cancer, 145(3), 678-685. https://dx.doi.org/10.1002/ijc.32137

MLA:
Bengs, Susan, et al. "β6-integrin serves as a novel serum tumor marker for colorectal carcinoma." International Journal of Cancer 145.3 (2019): 678-685.

BibTeX: 

Zuletzt aktualisiert 2019-21-06 um 11:08